Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond
Reads0
Chats0
TLDR
The ways in which S1P might be therapeutically targeted are discussed — for example, via the development of chemical inhibitors that target the generation, transport and degradation of S 1P and via thedevelopment of specific S1p receptor agonists.Abstract:
The bioactive lipid sphingosine-1-phosphate (S1P) is involved in multiple cellular signalling systems and has a pivotal role in the control of immune cell trafficking. As such, S1P has been implicated in disorders such as cancer and inflammatory diseases. This Review discusses the ways in which S1P might be therapeutically targeted — for example, via the development of chemical inhibitors that target the generation, transport and degradation of S1P and via the development of specific S1P receptor agonists. We also highlight recent conflicting results observed in preclinical studies targeting S1P and discuss ongoing clinical trials in this field.read more
Citations
More filters
Journal ArticleDOI
Lipid metabolic reprogramming in cancer cells
TL;DR: In it, detailed insight is provided into the essential roles exerted by specific lipids in mediating intracellular oncogenic signaling, endoplasmic reticulum stress and bidirectional crosstalk between cells of the tumor microenvironment and cancer cells.
Journal ArticleDOI
Natural product and natural product derived drugs in clinical trials
TL;DR: The next few years will be critical for NP-driven lead discovery, and a concerted effort is required to identify new biologically active pharmacophores and to progress these and existing compounds through pre-clinical drug development into clinical trials.
Journal ArticleDOI
The Concise Guide to PHARMACOLOGY 2013/14: Enzymes
Stephen P.H. Alexander,Helen E. Benson,Elena Faccenda,Adam J. Pawson,Joanna L. Sharman,Michael Spedding,John A. Peters,Anthony J. Harmar +7 more
TL;DR: The Concise Guide to PHARMACOLOGY 2013/14 provides concise overviews of the key properties of over 2000 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
Journal ArticleDOI
An update on the biology of sphingosine 1-phosphate receptors.
Victoria A. Blaho,Timothy Hla +1 more
TL;DR: This review will focus on the most recent advances in S1PRs, as they become attractive therapeutic targets in several diseases, such as chronic inflammatory pathologies, autoimmunity, and cancer.
Journal ArticleDOI
STAT3 Target Genes Relevant to Human Cancers
Richard L. Carpenter,Hui-Wen Lo +1 more
TL;DR: A review will be primarily focused on STAT3 downstream target genes that have been validated to associate with tumorigenesis and/or malignant biology of human cancers.
References
More filters
Journal ArticleDOI
Design and Synthesis of Selective and Potent Orally Active S1P5 Agonists
Henri Mattes,Kumlesh K. Dev,Kumlesh K. Dev,Rochdi Bouhelal,Carmen Barske,Fabrizio Gasparini,Danilo Guerini,Anis Mir,David Orain,Maribel Osinde,Anne Picard,Celine Dubois,Engin Tasdelen,Samuel Haessig +13 more
TL;DR: The studies of various benzamide modifications carried out to improve the selectivity, bioactivity, pharmacokinetic properties, and ancillary profile of 1 are reported, ultimately resulting in the discovery of potent and very selective S1P5 agonists.
Journal ArticleDOI
Efficacy of mycophenolic acid combined with KRP-203, a novel immunomodulator, in a rat heart transplantation model
Chihiro Suzuki,Masafumi Takahashi,Hajime Morimoto,Atsushi Izawa,Hirohiko Ise,Jun Fujishiro,Takashi Murakami,Junichi Ishiyama,Akihiro Nakada,Jun Nakayama,Kazuyuki Shimada,Uichi Ikeda,Eiji Kobayashi +12 more
TL;DR: Combination therapy of MPA with KRP-203 has a therapeutic potential as a novel immunosuppressant strategy in clinical transplantation.
Journal ArticleDOI
SAR Analysis of Innovative Selective Small Molecule Antagonists of Sphingosine-1-Phosphate 4 (S1P4) Receptor
Mariangela Urbano,Miguel Guerrero,Jian Zhao,Subash Velaparthi,Marie-Therese Schaeffer,Steven J. Brown,Hugh Rosen,Edward Roberts +7 more
TL;DR: By expanding the molecular diversity within the hit-derived class, the SAR study provides innovative small molecule potent and selective S1P(4) antagonists suitable for in vivo pharmacological validation of the target receptor.
Journal ArticleDOI
Prevention of GVHD and graft rejection by a new S1P receptor agonist, W-061, in rat small bowel transplantation
TL;DR: Data suggest that W-061 has considerable potential as a new therapeutic immunosuppressant in patients with small bowel transplantation (SBTx), as seen histopathologically in comparison with untreated control rats.